搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
来自MSN
15 分钟
Top Peptides for Hair Loss: Effective Solutions for Thicker Hair
Key Takeaways Peptides offer a non-invasive, natural approach to promoting hair growth and combating hair loss. They ...
2 小时
How screen time and stress may influence cancer risk in young people
Excessive screen time and chronic stress, especially in young people, disrupt circadian rhythms and immune function, ...
Medscape
1 天
Holistic Care of Hair Loss: Addressing Issues That Contribute to Loss and Regrowth
A holistic or integrative approach to hair loss considers the hair growth cycle and hair loss from a nutritional, ...
The American Journal of Managed Care
4 天
Resveratrol Oral Supplement Associated With Lower Rates of Intravitreal Aflibercept Injections
Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...
6 天
Phase III Trials: It’s crunch time for these ASX health stocks
Several ASX-listed companies are making significant strides in their phase III clinical trials, the critical final stage ...
American Association of Individual Investors
6 天
Why Compass Therapeutics, Inc.’s (CMPX) Stock Is Up 14.18%
Compass Therapeutics, Inc.’s CMPX share price has surged by 14.18%, which has investors questioning if this is right time to ...
6 天
Overview of common vision problems and medications
Medication is sometimes necessary to treat eye conditions and vision problems. Of course, this is highly dependent on the ...
News Medical
6 天
Study uncovers distinct blood protein signature in children with Long COVID
Distinct protein profiles linked to inflammation and angiogenesis found in children with Long COVID, paving the way for ...
7 天
on MSN
Regeneron's SWOT analysis: biotech giant's stock faces challenges, opportunities
Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex ...
Pharm Exec
7 天
FDA Grants Priority Review to Merck’s Welireg for Advanced, Unresectable, or Metastatic ...
Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈